We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fever Algorithm Development of a Non-invasive Wearable Core Body Temperature Sensor System in Intensive Care Unit Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04182945
Recruitment Status : Terminated (Not enough patients having fever symptoms)
First Posted : December 2, 2019
Last Update Posted : August 16, 2021
Sponsor:
Collaborator:
University of Zurich
Information provided by (Responsible Party):
greenTEG AG

Brief Summary:

Background and Rationale:

The gold standard to assess fever, is to conduct invasive intravascular, esophageal or bladder thermistor core body temperature (CBT) measurements. Since these methods are time consuming for the medical staff and more importantly displeasing to the patients, alternative CBT/fever assessments is needed. greenTEG is developing a CBT algorithm that will be able to reliably calculate CBT continuously form skin temperature (ST) and the corresponding heat flux (HF). This can be achieved from subjects developing fever in intensive care unit, since the prevalence of fever is high and optimally assessed.

Objective(s):

The aim of this study is to develop and validation of an algorithm that allows the detection of fever in patients through a non-invasive wearable prototype sensor, which calculates CBT from ST, HF and heart rate (HR) data streams, allowing a more effective patient management

Endpoint(s):

ST, HF, HR and CBT data are collected for at least 24hrs until 3 day, depending on the ICU length of stay of the patient. ST, HF, HR and CBT values from different measurement positions (subclavicular, lateral ribcage, upper arm and wrist) of the non-invasive wearable research prototypes will be compared with each other and compared to clinical invasive method particularly CBT measured by blood temperature from a pulmonary catheter if present or vesical temperature

Study Design:

Interventional-Single Group Assignment, monocentric, open label.

Statistical Considerations:

The measure of quality will be the mean absolute difference (MAD) between the CBT prediction and the reference signal where the mean is taken over the whole measurement of a single candidate. An aggregate performance measure over a group of candidates is defined by averaging the MAD values of each candidate in the group. When a group of candidates for algorithm validation is defined, the total improvement will be defined by comparing aggregate performances of old and new algorithm for the validation group. Balancing the probability of occurrence of the factors in the population and the overall size of the study, a final size of 50 candidates is reasonable.

Inclusion- / Exclusion Criteria:

Inclusion criteria:

  • Age ≥18 years old.
  • Patients which are treated at the cardiosurgical and vascular intensive care unit of the University Hospital Zurich.
  • Expected length of stay in the intensive care unit at least 24 hours
  • Clinical standard monitoring including an invasive CBT measurement (e.g. blood temperature from a pulmonary catheter if present or from a vesical catheter routinely placed)
  • Informed consent signed by the patient

Exclusion criteria:

  • Acute medical contraindications against the measurement of the non-invasive wearable device (e.g. skin diseases) and band-aid allergies.
  • Implanted pacemakers or other implanted life sustaining devices
  • Comatose state of the patient
  • Pregnant Women

Number of Participants with Rationale:

Number of participants in the study :50 candidates. The study will be divided in two parts. In the first part data are collected from 38 patients. In the second part, data form 12 patients will be collected. The reason for the first part is to collect data in order to develop the algorithm. The reason to collect additional data from 12 candidates in the second part is to validate and adjust the algorithm that is develop in the first part of the study.

Study Intervention:

50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist).

Control Intervention:

Not applicable

Study procedures:

Patients will be recruited and screened 1-3 days before the measurements starts. 50% of the research prototypes (4 pieces) will be applied to the patient on the left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. After the development of the fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). At the end of intervention all prototypes will be removed from the patient. A greenTEG employee will collect all the prototypes.


Condition or disease Intervention/treatment Phase
Fever Other: Data collection for algorithm development Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Fever Algorithm Development of a Non-invasive Wearable Core Body Temperature Sensor System in Intensive Care Unit Patients
Actual Study Start Date : December 11, 2019
Actual Primary Completion Date : January 31, 2021
Actual Study Completion Date : March 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever

Arm Intervention/treatment
Unobtrusive data collection
Unobtrusive data collection using noninvasive sensor systems.
Other: Data collection for algorithm development
50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). Data will be collected unobtrusively (no diagnosis will be made) and used for fever detection algorithm development.




Primary Outcome Measures :
  1. Continuous and non-invasive skin temperature and heat flux [ Time Frame: Participants will be monitored continuously and unobtrusively with the research prototypes over a 1-3 day time period, depending on the stationary stay in the ICU of the hospital. ]
    Skin temperature and heat flux data collected continuously and non-invasively using research prototypes at different measurement positions (subclavicular, lateral ribcage, upper arm and wrist).

  2. Continuous and invasive core body temperature [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Core body temperature data will be collected using the clinical standard method, which will be used to monitor patients on the ICU (pulmonary catheter or vesicular temperature).


Secondary Outcome Measures :
  1. Heart rate [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Heart rate [beats per minute] will be collected using the clinical standard method (ECG and pulse oximetry) used to monitor intensive care unit patients, which will be applied anyway (clinical standard procedure).

  2. Administration and dose of medication [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Administration and dose of medications will be tracked: norepinephrine, epinephrine, adrenaline, vasopressin, Levosimendan, Milrinone, analgesic and antipyretic drugs such as paracetamol.

  3. Blood pressure [ Time Frame: Data used will be limited to the time frame, where non-invasive methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Blood pressure [mmHg] will be collected using the clinical standard method (Intra-arterial measurements or clinical non-invasive BP monitor) used to monitor intensive care unit patients, which will be applied anyway (clinical standard procedure).

  4. ECG [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    ECG (graphic record of the voltage versus time) will be collected using the clinical standard method, which will be applied anyway (clinical standard procedure)

  5. Blood oxygen saturation [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Mixed venous oxygen saturation (SvO2) and peripheral capillary oxygen saturation (SpO2) will be collected using the clinical standard method (pulmonary artery catheter for SvO2 and pulse oximetry for SpO2) used to monitor intensive care unit patients, which will be applied anyway (clinical standard procedure).

  6. Blood lactate concentration [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Blood lactate concentration will be collected using the clinical standard method used to monitor intensive care unit patients, which will be applied anyway (clinical standard procedure).

  7. Cardiac Index [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Cardiac Index (L/min/m2) will be collected using the clinical standard method (Intra-arterial measurements) used to monitor intensive care unit patients, which will be applied anyway (clinical standard procedure).

  8. Fluid balance [ Time Frame: Will be avaluated every 24 hours for every day, where non-invasive CBT methods are applied (research prototype). 1-3 days depending on the stationary stay of the patient. ]
    Fluid balance will be collected using the clinical standard method used to monitor intensive care unit patients, which will be applied anyway (clinical standard procedure).

  9. Central venous pressure [ Time Frame: Data used will be limited to the time frame, where non-invasive CBT methods are applied (research prototype). This will be 1-3 days, depending on the stationary stay of the patient. ]
    Central venous pressure [mmHg] will be collected using the clinical standard method (central venous catheter) used to monitor intensive care unit patients, which will be applied anyway (clinical standard procedure).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years old.
  • Patients which are treated at the cardiosurgical and vascular intensive care unit of the University Hospital Zurich.
  • Expected length of stay in the intensive care unit at least 24 hours
  • Clinical standard monitoring including an invasive CBT measurement (e.g. blood temperature from a pulmonary catheter if present or from a vesical catheter routinely placed)
  • Informed consent signed by the patient

Exclusion Criteria:

  • Acute medical contraindications against the measurement of the non-invasive wearable device (e.g. skin diseases) and band-aid allergies.
  • Implanted pacemakers or other implanted life sustaining devices
  • Comatose state of the patient
  • Pregnant Women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04182945


Locations
Layout table for location information
Switzerland
University Hospital Zurich
Zürich, Switzerland, 8091
Sponsors and Collaborators
greenTEG AG
University of Zurich
Investigators
Layout table for investigator information
Principal Investigator: Dominique Bettex, Prof. Dr. University of Zurich
Layout table for additonal information
Responsible Party: greenTEG AG
ClinicalTrials.gov Identifier: NCT04182945    
Other Study ID Numbers: 6059_Fever_Study_1
First Posted: December 2, 2019    Key Record Dates
Last Update Posted: August 16, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The results of this study will be published in a suited journal. Publication strategy is still in discussion.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fever
Body Temperature Changes